Linked Life Data

15181417

Source:http://linkedlifedata.com/resource/pubmed/id/15181417

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2004-6-7
pubmed:abstractText
Pyruvic acid is a simple 3 carbon a-keto-monocarboxylic acid. Recognition that pyruvate is an effective scavenger of reactive oxygen species (ROS) prompted investigators to use it as therapeutic agent for various pathological conditions that are thought to be mediated by redox dependent phenomena, like myocardial, intestinal or hepatic ischemia/reperfusion-induced injury. Ethyl Pyruvate showed to be more effective and safer than equimolar doses of sodium pyruvate. Ethyl Pyruvate showed to have anti-inflammatory effects. In animal models Ethyl Pyruvate improved hyperpermeability and bacterial translocation due to endotoxemia and improved the development of renal disfunction as well as some of the morphological findings of kidney injury. The pharmacological basis for the anti-inflammatory effects of EP remains to be explained. It is plausible that EP mediates suppression of NF-KB activation and secretion of NO and of pro-inflammatory cytokines.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0375-9393
pubmed:author
pubmed:issnType
Print
pubmed:volume
70
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
365-71
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Ethyl pyruvate: a novel treatment for sepsis and shock.
pubmed:affiliation
Department of Critical Care Medicine, University of Pittsburgh Medical School, Pittsburgh, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S., Review